Long-Term Outcome of Hyper-CVAD-R for Burkitt Leukemia/Lymphoma and High-Grade B Cell Lymphoma: Focus on CNS Relapse

Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.